# Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)

> **NCT00152464** · PHASE3 · COMPLETED · sponsor: **UCB Pharma SA** · enrollment: 514 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Placebo
- **DRUG:** Levocetirizine

## Key facts

- **NCT ID:** NCT00152464
- **Lead sponsor:** UCB Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03-20
- **Primary completion:** 2006-03-15
- **Final completion:** 2006-03-15
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2019-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152464, "Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00152464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*